HC Wainwright Lowers BioNTech (NASDAQ:BNTX) Price Target to $136.00

Key Points

• HC Wainwright has lowered its price target for BioNTech (NASDAQ:BNTX) from $138.00 to $136.00 while maintaining a "buy" rating, indicating a potential upside of 21.57% from the current stock price.
• BioNTech reported a quarterly earnings miss with a loss of ($1.60) earnings per share, though revenue grew significantly by 102.6% year-over-year, reaching $306.46 million during the quarter.
• Major analysts have varied opinions on BioNTech, with five analysts rating it as hold and fourteen giving it a buy rating, resulting in an average price target of $135.80 from the firm's evaluations.

BioNTech (NASDAQ:BNTX - Get Free Report) had its price target cut by stock analysts at HC Wainwright from $138.00 to $136.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective points to a potential upside of 20.12% from the company's previous close.

Other equities research analysts have also recently issued research reports about the company. Morgan Stanley boosted their price objective on BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Bank of America upped their target price on shares of BioNTech from $126.00 to $134.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Truist Financial reissued a "buy" rating and issued a $155.00 price target (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. The Goldman Sachs Group initiated coverage on BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Price Performance

Shares of BNTX stock traded down $0.30 on Thursday, reaching $113.22. The company's stock had a trading volume of 33,902 shares, compared to its average volume of 930,568. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $81.20 and a 1 year high of $131.49. The company has a market capitalization of $27.22 billion, a price-to-earnings ratio of -70.81 and a beta of 1.23. The stock's fifty day simple moving average is $109.42 and its 200-day simple moving average is $105.70.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%. The firm's revenue was up 102.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($3.36) earnings per share. Analysts forecast that BioNTech will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. Banque Cantonale Vaudoise acquired a new position in shares of BioNTech in the first quarter valued at approximately $36,000. LRI Investments LLC increased its stake in BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company's stock worth $47,000 after acquiring an additional 312 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after buying an additional 305 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in BioNTech by 472.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock worth $61,000 after buying an additional 472 shares during the last quarter. Finally, Banque Transatlantique SA bought a new position in BioNTech during the 1st quarter worth $80,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.